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Dendritic Cells (DCs) recognize infectious non-self molecules and engage the adaptive immune 
system thereby initiating long lasting, antigen-specific responses. As such, the ability to activate DCs 
is considered a key tool to enhance the efficacy and quality of vaccination. Here we report a novel 
immunomodulatory sulfolipid named β-SQDG18 that prototypes a class of natural-derived glycolipids 
able to prime human DCs by a TLR2/TLR4-independent mechanism and trigger an efficient immune 
response in vivo. β-SQDG18 induces maturation of DC with the upregulation of MHC II molecules and 
co-stimulatory proteins (CD83, CD86), as well as pro-inflammatory cytokines (IL-12 and INF-γ). Mice 
immunized with OVA associated to β-SQDG18 (1:500) produced a titer of anti-OVA Ig comparable 
to traditional adjuvants. In an experimental model of melanoma, vaccination of C57BL/6 mice with 
β-SQDG18-adjuvanted hgp10 peptide elicited a protective response with a reduction in tumour growth 
and increase in survival.
Stimulation of an immune response by using attenuated or inactivated biological agents has been the traditional 
basis for vaccination against viral and bacterial infections. However, most of the recent vaccines are comprised of 
highly purified synthetic macromolecules, such as peptides or recombinant DNA produced by genetic engineer-
ing technology. These antigens tend to be safer but poorly immunogenic; therefore they need to be combined with 
agents known as adjuvants that potentiate the immune response mostly by activation of specific accessory cells, 
named Antigen-Presenting Cells (APCs)1–6. Adjuvants are a highly heterogeneous group of compounds with 
a common property¸ usually defined as adjuvancy, to enhance the immunogenicity of antigens. Nevertheless, 
except for the Toll-like receptor (TLR) agonist monophosphoryl lipid A (MPLA, compound 1 in Fig. 1), clini-
cally approved formulations are restricted to aluminium salts and emulsions of lipids (e.g. squalene) in water7. 
Dendritic cells (DCs) are the most efficient APCs8–14 and are often called ‘nature’s adjuvant’15 for their ability 
to induce activation and specific expansion of CD4+ helper T (Th) and CD8+ cytotoxic T (CTL) lymphocytes 
determining the functional profile of these cells against bacterial and viral antigens15. For these reasons DCs have 
become the product of choice for the preparation of DC-based vaccines against tumors or infections16–19.
Here we provide the first evidence of a novel class of molecular adjuvants of marine origin able to stimulate 
in vitro DC maturation and prime in vivo specific immune response.
1Bio-Organic Chemistry Unit, CNR- Institute of Biomolecular Chemistry, Via Campi Flegrei 34, IT-80078, Pozzuoli, 
Napoli, Italy. 2University of Campania, Clinical Immunology and Allergology, Dept. of Internal and Experimental 
Clinic, c/o II Policlinico (Bd. 3), Via S. Pansini, 5, 80131, Napoli, Italy. 3Stazione Zoologica “A. Dohrn”, Villa Comunale, 
80121, Napoli, Italy. 4University of Campania, Dept. of Experimental Medicine, c/o II Policlinico (Bd. 3), Via S. Pansini, 
5, 80131, Napoli, Italy. 5Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy. 6Department 
of Internal Medicine, University of Genoa, Genoa, Italy. 7Univeristy of Naples “Federico II”, Department of Molecular 
Medicine and Medical Biotechnology, c/o II Policlinico (Bd. 3), Via S. Pansini, 5, 80131, Napoli, Italy. 8Institute of 
Protein Biochemistry, via P. Castellino, 111, 80131, Napoli, Italy. Correspondence and requests for materials should 
be addressed to R.D.P. (email: raffaele.depalma@unicampania.it) or A.F. (email: afontana@icb.cnr.it)
Received: 11 January 2017
Accepted: 6 June 2017
Published online: 24 July 2017
OPEN
www.nature.com/scientificreports/
2SCIENtIfIC REPORtS | 7: 6286 | DOI:10.1038/s41598-017-05969-8
Results
Response of Dendritic cells to natural marine lipids. DCs are heterogeneous and derive from pro-
genitors in the bone marrow from where they migrate to all tissues in the body. Monocytes are also able to 
differentiate into dendritic cells (MoDCs) when subjected to an inflammatory stimulus; these cells are able to 
preserve the main characteristics of normal APCs10, 20. Fully differentiated MoDCs efficiently present soluble 
and cell-associated antigens to T cells and show stimulating capacity comparable to tissue-derived DCs21. In this 
study, human MoDCs were placed in 96 multiwell plates and treated with methanol extracts from a collection of 
marine organisms including invertebrates and photosynthetic protists (microalgae, diatoms and dinoflagellates). 
Evolution from immature antigen-capturing cells to mature, immunologically competent DCs was assessed by 
measuring the expression of MHC-Class II receptor HLA-DR and the co-stimulatory molecule CD86 by flow 
cytometry22. When mature DCs were detected, we also measured production of IL-12, a specific mediator of 
Th1/CTL activation23–25, by quantitative PCR. Extracts from different diatom species gave positive hits with the 
major activity associated to fractions containing glycolipids. One of the most active species, namely Thalassiosira 
weissflogii (CCMP-1336), was mass cultivated (300 g dry weight) in 70 L photobioreactors. Extraction by SPE and 
bioassay-guided fractionation led to the isolation of a mixture of α-sulfoquinovosyl diacylglycerols (α-SQDGs, 2) 
that induced overexpression of IL-12 at 10 µg/mL and HLA-DR at 10 ng/mL (Fig. 1). α-SQDGs are relatively 
minor lipids compared to galactosylglycerides in plants but their content is usually higher in algae and microal-
gae. They are concentrated in the inner membranes of chloroplasts but their function is still unclear. Instead of 
the phosphate group of MPLA, α-SQDGs are characterized by a sulfur atom directly linked to the carbon 6′ of a 
single unit of monosaccharide referred to as sulfoquinovose (Fig. 1). Furthermore, compared to immunogenic 
bacterial glycolipids that usually have a β-configuration of anomeric carbons, α-SQDGs have an α-configuration 
of the sugar unit. Lipid profiling by LC-MS26 of T. weissflogii revealed that the natural active fraction was com-
posed of a mixture of α-SQDGs differing in the composition and position of saturated or monounsaturated fatty 
acids, mainly palmitic (16:0) and palmitoleic (16:1) acids (Fig. 1). The immunostimulatory activity of this class of 
lipids was further confirmed by the effect of a few synthetic analogs (3-5)27 that were all able to elicit maturation 
and IL-12 production of DCs regardless of the presence of C16 or C18 alkyl chains.
Activation of DC by the synthetic sulfolipid β-SQDG18. Inspired by the structure of MPLA (1), we 
also designed a chimeric molecule, named β-SQDG18 (compound 6 in Fig. 2), that combined the presence of the 
sulfonic residue typical of α-SQDGs with the β-configuration of the glycosidic bond that is common in immu-
nogenic LPS-related glycolipids28. The chimeric sulfolipid (6) was synthesized by coupling 1,2-O-isopropylidene 
glycerol with the trichloroacetamidate derivative of tetra-acetyl glucose (Supplementary Information)29. After 
Figure 1. Chemical structure and DC activation of natural sulfoquinovosides (α-SQDG) from marine diatoms. 
(A) Structures of DC agonists: monophosphoryl lipid A (MPLA, 1) (reference compound), natural α-SQDG 
(2) and synthetic (3-5) α-SQDG. Colors underline the chemical differences in type and position of the anionic 
function, configuration of the anomeric carbon, second sugar residue and fatty acid acyl chain between 
MPLA (1) and α-SQDG (2-5); (B) LC-MS profile of active α-SQDG (2) in the extract of the marine diatom 
Thalassiosira weissflogii. The insert reports the type and distribution of fatty acids bound to the sulfoquinovosyl 
glycerol residue; (C) expression of IL-12 (mean/standard deviation) and (D) expression of HLA-DR by 
MoDCs stimulated with natural and synthetic analogs of α-SQDG at 10 ng/mL and 10 µg/mL. Results (mean 
+/− standard deviation) are reported as percentage of positive cells (marker expression value over 104) out of 
the total DC population. LPS was used as positive control. Asterisks indicate significant differences from the 
cells treated only with vehicle (control, Ctr) at a 95% (P < 0.05) confidence level, as determined using two-way 
ANOVA analysis.
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selective de-protection of the primary hydroxyl group at C-6′, the carbon-sulfur bond was introduced through 
a thioacetate intermediate from which 1,2-distearoyl-3-O-(β-sulfoquinovosyl)-sn-glycerol (β-SQDG18, 6) was 
obtained by conventional chemical reactions. In comparison with natural sulfolipids, β-SQDG18 (6) showed an 
increased potency in promoting maturation of MoDCs as proved by the up-regulation of phenotypic markers 
in a dose-dependent manner from 10 ng/mL to 10 µg/mL. As reported in Fig. 2, the molecule increased the 
percentage of CD83-positive cells. High expression of this marker on the cell surface is a peculiarity of fully 
matured human DC30, 31 and critical for the in vivo priming of naïve T cells32, 33. Furthermore, upregulation of 
CD83 prevents MHC II and CD86 down-regulation induced by IL-10 through MARCH1 thus enhancing the 
immunogenicity of vaccine adjuvants34. Expression of CD86 by β-SQDG18 (6) was quantitatively not different 
from that induced by the TLR agonist Pam2CSK4 although the two molecules showed different ability to promote 
surface display of HLA-DR. β-SQDG18 (6) induced only a slight increase of MHC class II molecules that are con-
stitutively expressed at high levels in DCs. The synthetic sulfolipid also stimulated production of a distinct array 
of pro-inflammatory cytokines including IL-12 (about 130-fold increase compared to control DMSO and about 
25-fold increase compared to natural α-SQDG) and INF-γ, that are related to the DCs’ ability to prime an efficient 
Th1 cell response23, 35. In addition to these results, PCR array analysis of 96 genes in DCs stimulated by β-SQDG18 
(6) showed an up-regulation of CD40 ligand, IL-27 and other interleukins (e.g. IL-1α and IL-1β, IL-18) that work 
synergistically to induce Th1 cells and play a major role in resistance to bacterial and viral infections, as well as to 
tumours (Supplementary Material).
β-SQDG18 does not activate TLR2 and TLR4 response. The immune effect of MPLA (1) and many 
glycolipids of interest as vaccine adjuvants (e.g. lipoteichoic acid) is mediated by Toll-like receptors (TLRs), 
mainly TLR-2 or TLR-436. TLRs are principal membrane-associated innate sensors that DCs and other APCs 
use to recognize conserved pathogen-associated molecular patterns (PAMPs). To verify whether β-SQDG18 (6) 
activity were TLR-2/TLR-4 dependent, we tested β-SQDG18 (6) effects in a cell-based assay with HEK293 sta-
bly co-transfected to express full-length human TLR-2 or TLR-4 and the secreted alkaline phosphatase (SEAP) 
reporter gene under the transcriptional control of a NF-kB response element37. As shown in Fig. 2D, the sulfolipid 
had no effect on reporter activation of either receptor at concentrations that stimulate maturation and cytokine 
production by DCs. Down-regulation on TLR-4 in an array analysis of 84 genes of DCs stimulated by β-SQDG18 
(6) further supported a TLR-independent mechanism for the activation of these cells (Supplementary Material).
Figure 2. Dose-dependent priming of DC by βSQDG18 (6). (A) The chimeric molecule β-SQDG18 
(6) derives from combination of the structural characteristics of α-SQDG (yellow) and MPLA (green); 
(B) Flow-cytometry analysis of the phenotyping markers of DC maturation (HLA-DR, CD83 and 
CD86) at concentrations between 10 ng/ml to 10 µg/ml of β-SQDG18 (6). gray = isotype control; dark 
gray = unstimulated cells; orange = stimulated cells. Pam2CSK4 (PAM) was used as positive control; (C) 
expression of IL-12 and IFN-γ by DC stimulated with β-SQDG18 in the same range of concentrations used 
for the above marker phenotyping; (D) evaluation of the Toll-Like Receptor (TLR) activation by increasing 
concentration concentrations of β-SQDG18 in TLR-2 and TLR-4 NF-kB/SEAP reporter cell lines. Pam2CSK4 
(PAM) and LPS were used as positive controls for TLR-2 and TLR-4 respectively. Asterisks indicate significant 
differences from the cells treated only with vehicle (control, Ctr) at a 95% (P < 0.05) confidence level, as 
determined using two-way ANOVA analysis.
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Immunization of mice against ovalbumin using β-SQDG18 as adjuvant. In order to acquire con-
clusive evidence about the potential of the synthetic sulfolipid to boost immune protection and to act as an adju-
vant, the synthetic lipid was tested in animal models. First, we evaluated the antibody response in mice following 
immunization with OVA, as model antigen, associated to β-SQDG18 (6). To this aim, a sterile saline solution was 
formulated by mixing the protein with the synthetic sulfolipid 6 obtained by scale-up of the chemical procedure 
discussed above. Control groups received OVA delivered in DMSO or formulated with either complete Freund’s 
adjuvant (CFA) or TiterMax® (TM). Following subcutaneous injections of 5 µg OVA and 2.5 mg β-SQDG18 at 
day 1 and 8, the animals responded by day 21 with a robust enhancement of anti-OVA antibody titer (Fig. 3). In 
analogy with the control adjuvants CFA and TM, immunization with OVA/β-SQDG18 evoked increase of IgG1 
and IgM. There is no univocal understanding of antibody function in mouse; however, there is good agreement 
about the role of IgM in early response, as well as of IgG1 in mitigation of the inflammatory process. In addition 
to IgG1, murine IgGs include IgG2a, IgG2b and IgG3, whose production is stimulated to different extents by the 
sulfolipid. Recently Collins has discussed the model of murine IgG response by concluding that these four classes 
of antibodies work synergistically and their actions have to be considered together38. In this view, the humoral 
response due to OVA/β-SQDG18 was comparable to the antibody titer associated with co-administration of OVA 
with the known adjuvants CFA or TM.
Comparative analysis of adjuvants in vaccines against an experimental melanoma model. In a 
second strategy of immunization, we tested β-SQDG18 (6) in an experimental model of cancer vaccine against a 
murine B16F10 melanoma cell line, that is widely used for therapeutic evaluation39. Activating immune responses 
against cancer is considered a promising therapeutic approach even if the clinical application of therapeutic can-
cer vaccines is currently hampered by the difficulties in the selection of effective immunization protocols. In 
fact, the weak antigenicity of many tumor antigens requires the association with robust adjuvants to boost the 
cell-mediated immune response40. In our experiment, β-SQDG18 (6) was tested in mice challenged with the 
human gp10025–33 (hgp10025–33) peptide, an antigen derived from a melanocyte differentiation protein41, 42. The 
adjuvant effect of β-SQDG18 (6) was compared with those of Freund’s and CpG Oligodeoxynucleotide (CpG) 
adjuvants. Vaccines formulated with CpG have shown to elicit both cellular and humoral responses so that the 
oligonucleotide has been tested in clinical and preclinical trials43, 44. In agreement with a previous protocol of vac-
cination showing a protective effect of hgp10025–33 peptide in association with CpG45, we immunized mice with 
the melanoma epitope for two weeks before challenging with B16F10 melanoma cells (1 × 105 cells per mouse) 
(Fig. 4). In line with the previous results45, the three treatments reduced tumour growth and prolonged survival 
in comparison to control animals challenged only with B16F10 cells. Association of β-SQDG18 to hgp10025–33 
peptide induced in vivo expansion of both memory lymphocytes and APCs, as indicated by the increase in the 
percentage of CD8+CD44 high T lymphocytes and CD3-CD19-CD80+ cells among splenocytes in immunized 
mice in comparison with unvaccinated tumour-challenged animals (Fig. 4E and F). The protective activity of 
Figure 3. Humoral response of mice after immunization to ovalbumin formulated with β-SQDG18. C56 
BL/6 mice were divided into 4 groups and inoculated twice with 5 µg antigen (OVA) in presence or absence 
(Control) of 2.5 mg β-SQDG18 (1:500 w/w). Co-administrations of OVA together with Complete Freund’s 
Adjuvant (FCA) or TiterMax (TM) were used as positive controls. Serum anti-OVA antibodies were measured 
by ELISA and results are shown as endpoint titer (mean/standard error). No increase in OVA-specific IgA was 
observed. Asterisks indicate significant differences from the control group at a 95% (P < 0.05) confidence level, 
as determined using two-way ANOVA analysis.
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vaccination with hgp10025–33 in association with β-SQDG18 (6) was comparable with the effect of the other 
two immunizing protocols (Fig. 4), thus providing the final proof of the efficacy of this molecule in the vaccine 
formulation.
Discussion
For more than 70 years, aluminum salts have been the only adjuvants licensed for human use worldwide46. In 
the last decades, the improved understanding of how innate mechanisms influence the adaptive immunity has 
made possible the development of new adjuvants in a more rational design. A major breakthrough has been the 
approach of stimulating antigen-presenting cells, mostly DCs, that efficiently engage the adaptive immune sys-
tem1–5. Screening of a library of extracts from marine microalgae for stimulation of human monocyte-dendritic 
Figure 4. Protective effect of hgp10025–33 peptide formulated with synthetic β-SQDG18 as adjuvant in an 
experimental model of anti-melanoma vaccine. (A) Experimental design of immunization in C57BL/6 J 
mice challenged by 105 B16F10 melanoma cells (day 0). The animals were pretreated with the adjuvanted 
antigen hgp10025–33 peptide (100 μg mouse/injection) on days −14, −7 and 0. For the experiment with 
β-SQDG18 (600 μg mouse/injection), the antigen was vigorously mixed with a homogeneous suspension of 
the molecule prior to injection. Mice immunized with the melanoma epitope in association to either CPG 
oligodeoxynucleotide (30 μg/injection) or Freund’s adjuvants (1:1 vol/vol) were used as positive controls. 
Unimmunized mice were used as negative control. Tumour volume of melanoma lesions and survival rate were 
monitored for 30 days after challenging. Each group was composed of eight animals; (B) Tumour growth and 
(C) percent survival in the four groups of mice. Statistically significant difference between the negative control 
and each of the three immunized groups of mice is indicated. Black line: negative control; Red line: antigen plus 
β-SQDG18; Green line: antigen plus Freund’s adjuvant; Orange line: antigen plus CpG; (D) Detail of tumour 
growth in response to vaccination with the three adjuvants. Groups are indicated by colours as above Asterisks 
indicate statistically significant differences in comparison to negative control. *P < 0.01; **P < 0.002; (E) 
Percentage of CD8+CD44high memory T cell in splenocytes of tumour-challenged mice in the negative control 
group or after vaccination by β-SQDG18 as adjuvant (black column); (F) Percentage of CD3-CD19-CD80+ cells 
in splenocytes of tumour challenged mice in the negative control group and after vaccination by β-SQDG18 as 
adjuvant (black column).
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cells (hMo-DCs) gave positive hits associated with α-sulfoquinovosides (Fig. 1), natural glycolipids wide spread 
in photosynthetic organisms but very rich in microalgae. In the last years, the emerging role of small molecules 
and lipids in immunogenicity has gained significant research traction1, 47–55. Marine lipids often do not have 
counterpart in terrestrial organisms and are considered a potential source of novel immunogenic compounds. 
The algal products showed only a little activity but modification of their structure led to the synthetic analog 
β-SQDG18 (6) that induces maturation of human DCs, production of inflammatory cytokines (Fig. 2) and boosts 
the immune protective response in vivo (Figs 3 and 4). Considering the difference in the stimulatory activities 
between the synthetic molecule and the natural products, introduction of saturated fatty acids bound to glycerol 
and β-configuration of the anomeric carbon are the major determinants of the DC response. This is likely due to 
the resemblance of the synthetic molecule with bacterial lipids that, differently from those found in mammalians 
and plants, are mainly made of saturated alkyl chains.
The DC activation by β-SQDG18 (6) is TLR-independent as the molecule did not activate TLR2- or 
TLR4-dependent cell lines (Fig. 2D). In consideration of the chemical structure of the sulfolipid and the close 
analogies with LPS-related adjuvants (e.g. MPLA)56, this result was rather surprising. However, DCs maturation 
does not necessarily require TLR-mediated triggering and a few bacterial molecules, also currently considered 
as vaccine adjuvants, can directly stimulate DC function without activation of TLR signaling pathways57. As the 
cell-based assay measures LPS response at the ng range, the absence of appreciable signal also excludes the con-
tamination of the tested samples of β-SQDG18 (6) with small amounts of the lipopeptides.
DC stimulation is of central interest in the development of preventive and therapeutic vaccines against can-
cer19, 40. As shown in Fig. 4, β-SQDG18 (6) reduced tumor size and prolonged animal survival in an experimen-
tal model of vaccination against melanoma in mouse. Use of the sulfolipid gave results very similar to those 
achieved by well-established adjuvants, such as CpG and Complete Freund’s Adjuvant. Notably, vaccination with 
β-SQDG18 and CpG, but not Freund’s, also resulted in the delay of tumour growth in the first ten days after chal-
lenging (Fig. 4). Stimulation of DCs is extremely well suited to activate T-cell response in patients with cancer 
and, very recently, the clinical efficacy of this strategy has been proven in an innovative approach using nano-
particles of RNA–lipid complexes58. The demonstration that β-SQDG18, as CpG, targets DCs and induces their 
activation and maturation suggests that the protective effect of both adjuvants in the first days after vaccination 
correlates with the enhancement of the immunogenicity of hgp10025–33. These results are very encouraging for 
further testing of β-SQDG18 in anticancer formulations.
Taken together, these data pave the way to a new class of adjuvants based on a single molecule. Formulation of 
these products offers a few technical advantages because it does not require additional products (i.e. surfactants) 
and the dosage of the single product is straightforward. This simplifies the evaluation of the biological response 
too. Importantly, we also demonstrated that preparation of the sulfolipid molecule can be scaled by standard 
chemical methods in order to fulfil the supply need for clinical development. Chemical modifications of the 
product and optimization of the formulation protocol will probably allow reduction of the amount of β-SQDG18, 
thus further improving safety and efficiency of vaccination protocols.
Methods
All methods were performed in accordance with the local regulations and relevant guidelines of CNR –Institute 
of Biomolecular Chemistry and Department of Internal and Experimental Clinic of the University of Campania. 
Mice were handled and treated according to the guidelines provided in Ministero della Salute D.lgs 26/2014 under 
the supervision of the Animal Facility OPBA of the National Health Service - University Hospital San Martino 
of Genoa.
General Experimental Procedures. 1D- and 2D-NMR spectra were recorded on AVANCE™III HD 
400 MHz spectrometer (Bruker Bio-Spin, Fällanden, Swiss) and Bruker DRX 600 MHz spectrometer (Bruker 
Bio-Spin, Fällanden, Swiss) equipped with a TXI CryoProbe in CDCl3 and CD3OD (δ values are referred to 
CHCl3 and CH3OH at 7.26 and 3.34 ppm respectively). Mass analyses were aquired on a Micromass® Q-Tof 
micro™ mass spectrometer coupled with an Alliance HPLC System (Waters Corp., Milford, MA, USA) or on a Q 
Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Scientific,Waltham, MA, USA) coupled 
with an 1290 Infinity UPLC System (Agilent Technologies, Santa Clara, CA, USA). Solvents (LC-MS grade), TLC 
plates (Kieselgel 60 F254) and silica gel powder (Kieselgel 60, 0.063–0.200 mm) were from Merck (Darmstaadt, 
Germany). Other solvents were purchased from VWR (Radnor, PA, USA). All the reagents were obtained from 
Sigma-Aldrich (Saint-Louis, Mo, USA) and used without any further purification.
Algal culturing. Thalassiosira weissflogii was cultured in 70 L photobioreactors filled with 0.22 μm FSW 
enriched with f/2 medium. Cultures were gently bubbled with filtered ambient air and grown in a climate cham-
ber at 20 °C under 12 h:12 h light:dark cycle (100 μmol photons·m2·s−1). Cells were harvested at the stationary 
phase by centrifugation at 3750 rpm for 10 min at 4 °C in a swing-out rotor.
Extraction and isolation of complex lipids from marine diatoms. For preliminary biological screen-
ing, microalgal extracts were prepared and fractionated according our previous protocol59. Briefly methanol 
extracts were obtained from wet pellet (about 200 mg) and fractionated (about 20 mg) on HRX column by using 
five eluents, i.e. A, H2O 100%; B, MeOH/ H2O 1:1, C, ACN/ H2O 7:3; D, ACN 100% and E, CH2Cl2/MeOH 9:1. 
α-SQDG eluted in fraction C. For preparative purposes, MeOH extract of T. weissflogii was chromatographed on 
Sephadex LH-20 column by using CHCl3/MeOH (1:1) as eluent. Fraction containing sulfoquinovosides was fur-
ther purified by radial silica chromatography on Chromatotron (T-Squared Technology Inc, San Bruno, CA, USA) 
by CHCl3:MeOH and CHCl3:MeOH:H2O, 65:25:4. Pure α-SQDGs were characterized by NMR and MS methods.
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LC-MS/MS Analysis of natural α-SQDG. Species composition was identified by LC-MS/MS according 
to our recent report26. Briefly, UPLC separation was performed on a Kinetex Biphenyl (2.6 µm, 150 × 2.1mm) 
column (Phenomenex, Torrance, CA, USA) by using a binary mobile phase of water and methanol (MeOH). The 
elution program (flow rate 0.3 mL/min) was from 40% to 80% MeOH in 2 min, then 100% MeOH in 13 min and 
100% MeOH for other 7 min. Full scan mass spectra (ESI in negative ion mode) were acquired in the m/z range 
150–2000 with a resolution of 70000. MS/MS experiments on monoisotopically isolated precursor ions were 
performed with a normalized collision energy between 20 and 40.
Glycolipid synthesis. Synthetic analogs 3-5 were prepared according to Manzo et al.27. Synthesis of com-
pounds 6 is described in the Supplementary Information. 1,2-distearoyl-3-O-β-D-sulfoquinovosy]-(R/S)-
glycerol (6): 1,2-distearoyl-3-O-[(2′,3′,4′-tri-acetyl-)-β-D-sulfoquinovosyl]-(R/S)-glycerol (0.40 g, 0.00040 mol) 
was dissolved in aq. ethanol (85%) (30 mL), hydrazine monohydrate (0.16 g, 0.00336 mol) was added, and the 
reaction mixture was stirred for 3 h at 44 °C. After evaporation under a stream of nitrogen, the mixture was 
purified by silica gel chromatography using a gradient of chloroform/methanol to give 1,2-distearoyl-3-
O-β-D-sulfoquinovosy]-(R/S)-glycerol (6) (0.26 g, 0.00030 mol, 70%) as a white solid, m.p. 88–92 °C; Rf (chlo-
roform/methanol 7:3) = 0.15; IR (liquid film) vmax 3400, 2940, 2862, 1750, 1351, 1343 cm;-1 1H-NMR (400 MHz, 
CDCl3/CD3OD 1/1): 1H-NMR (400 MHz, CDCl3/CD3OD 1/1): δ 5.29 (1H, m, m, H-2), 4.47 (1 H, m, H-1a), 4.34 
and 4.32 (each for 1 H, d, 7.8 Hz, H-1′), 4.19 (1 H, m, H-1b), 4.13–4.03 (1 H, m, H-1a), 3.79–3.75 (2 H, m, H-3b, 
H-5′), 3.42 (1 H, m, H-3′), 3.32 (1 H, m, H-6′a), 3.26 (1 H, m, H-2′), 3.14 (1 H, m, H-4′), 2.98 (1 H, m, H-6′b), 
2.43–2.35 (4 H, m, α-methylene), 1.69–1.58 (4 H, m, β-methylene), 1.43–1.29 (acyl chain), 0.94 (6 H, overlapped, 
2 CH3); HRESIMS m/z 849.5757 [M-K]− (calcd for C45H85O12S−, 849.5767).
Preparation of Dendritic Cells. For each assay human peripheral blood mononuclear cells were iso-
lated from two healthy donors by routine Ficoll density gradient centrifugation. Monocytes were purified from 
human peripheral blood mononuclear cells using MACS CD14 microbeads (Miltenyi Biotech, Auburn, CA, 
USA) according to the manufacturer’s recommendation. Purity was checked by staining with a FITC-conjugated 
anti-CD14 antibody (Milteny Biotech, Auburn, CA, USA) and FACS analysis and was routinely found to be 
greater than 98%. Immature DCs were obtained by incubating monocytes at 1∙106/mL in RPMI 1640 medium 
supplemented with 10% fetal calf serum, 1% L-glutamine 2 mM, 1% penicillin and streptomycin, human IL-4 (5 
ng/mL) and human GM-CSF (100 ng/mL) for five days.
Cells Staining and stimulation. After five days in culture, surface staining was performed on 
monocyte-derived dendritic cells (MoDC) for flow cytometry analysis. In the initial screening assay moDCs 
were stained to check the maturation state with mouse anti-human HLA-DR-PE (BD PharMingen, Haryana, 
India), CD86-FITC, CD3-PerCP (Milteny Biotech, Auburn, CA, USA) and CD14-FITC monoclonal antibodies. 
Then the experiments were conducted by using the following conjugated mAbs from BD Biosciences (Milano, 
Italy): CD14Fitc, CD1a-BUV121, CD86 BV650, CD83BUV737, HLA-DRBV786, CD11c-BUV395, CD3 BV510, 
CD54Pe, CD1c Alexa Fluor 647, CD4- PeCys7, and analyzed by flow-cytometer on LSRFortessa™ X-20 cell ana-
lyzer (BD Bioscience, Frankin Lake, NJ, USA) according to standard protocol. MoDC were then incubated with 
natural and synthetic compounds in 12-wells. Stimulation with Pam2CSK4 1 µg/mL (Invivogen, San Diego, CA, 
USA) was used as positive control. Cells treated only with vehicle (DMSO) were used as control. Release of 
cytokines was measured by LUMINEX® platform by Human IL-12p70 Luminex Performance Assay and Human 
TNF-alpha Luminex Performance Assay according to manufacturer’s instructions (R&D Systems, Minneapolis, 
MN, USA). After 24 hours, expression of all surface markers was estimated again by fluorochrome-conjugated 
antibodies.
Real Time PCR analysis. Total RNA was isolated using Trizol Reagent, according to the manufactur-
er’s protocol. RNA quantity and purity were measured with a NanoDrop 2000 spectrophotometer (Thermo 
Scientific,Waltham, MA, USA). Sample purity was checked by A260/A280 ratios between 1.80 and 2.00. Extracted 
RNAs from all preparations were in this range. Cytokines mRNA expression was measured by quantitative Real 
Time-PCR. Results are expressed as means ± SD. All data were analyzed by one way ANOVA followed by the 
Tukey test for multiple comparison test. A p-value less than 0.05 was considered as statistically significant. All 
analyses were performed using the GraphPad Prism 4.00 for Windows software (GraphPad Software, San Diego 
California, USA).
PCR Array analysis. About 200 ng RNA was subjected to reverse transcription reaction using the RT2 first 
strand kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The qRT-PCR analysis was 
performed in triplicate using the RT2 Profiler PCR Array kit (Qiagen, Hilden, Germany), in order to analyse the 
expression of inflammatory cytokines and receptors on dendritic cells stimulated. Plates were run on an Applied 
Biosystem ViiA 7 Real-Time PCR System (384 well blocks) (Thermo Scientific,Waltham, MA, USA) by Standard 
Fast PCR Cycling protocol with 10 µl reaction volumes. Cycling conditions used were: 1 cycle initiation at 95.0 °C 
for 10 min followed by amplification for 40 cycles at 95.0 °C for 15 s and 60.0 °C for 1 min. Amplification data were 
collected via A ViiA 7 RUO Software (Applied Biosystems). The cycle threshold (Ct)-values were analyzed with 
PCR array data analysis online software (Qiagen, Hilden, Germany).
TLR assay. Human TLR-4/NF-kB/SEAP and TLR2/ NF-kB/SEAP (SEAPorter™) HEK 293 reporter cells 
(Novus Biologicals, Littleton, CO, USA) were plated in 24-well plates at 2×105 cells/well. After 16 hours, for 
functional assays, TLR4 cells, cells were transiently transfected with MD2/CD14 plasmid vector (Invivogen, San 
Diego, CA, USA) for 24 hours. Cells were then stimulated with β-SQDG18 for 24 hours. LPS for TLR-4 cell line 
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and Pam2CSK4 for TLR-2 cell line were used as positive control under the same conditions. SEAP was analyzed 
using the SEAPorter Assay (Novus Biologicals, Littleton, CO, USA) in according to manufacturer’s instructions. 
Quantitative data (ng/mL) were obtained by a standard curve for the SEAP protein.
Immunization protocol. Immunization of C56BL/6 mice (four groups of three individuals) was carried 
out by injecting twice 5 µg Ovalbumin (OVA) (Hyglos GmbH, Bernried am Starnberger See, Germany) together 
with 2.5 mg β-sulfoquinovoside mixture (6) according to published protocols60. OVA-specific Ig production was 
measured by ELISA according to Leung S et al.61. Titermax and Complete Freund’s Adjuvant (Sigma Aldrich, 
St. Louis, MO, USA) were used according to manufacturer instructions. Statistical analyses were performed by 
ANOVA using the GraphPad Prism 4.0 Software (GraphPad Software, Inc, La Jolla, CA).
Comparative analysis of cancer vaccine formulations. Experiments were carried out according to 
the published protocol45 by challenging C57BL/6 J mice with subcutaneously injection of B16F10 melanoma 
cells (1 × 105 cells/mouse). Prior to challenge, the animals were immunized three times at days −14, −7 and 
0 by subcutaneous injection of hgp10025–33 peptide (100 μg/mouse injection) in association with one of the fol-
lowing products: CpG (30 μg) (Tib MolBiol, Genoa, Italy), Freund’s adjuvant (1:1 vol/vol) (Sigma Aldrich, St. 
Louis, MO), β-SQDG18 (600 μg). Formulations were carried out according to manufacturers’ instructions. For 
β-SQDG18, the melanoma antigen was simply added to a stable emulsion of the sulfolipid in phosphate buffer 
prior to injection. Experiments were carried out on groups of 8 animals each. Tumor masses were measured with 
a caliper at 2–3 days intervals by measuring long and short axes. Volume was calculated according to the formula: 
tumor volume = ½ (length × width2) in cm3. Mice were sacrificed when either tumors reached > 1 cm3, when 
ulceration/bleeding developed, or after 30 days from the tumor challenge. Mice treated with hgp10025–33 peptide 
alone prior to challenging with B16F10 cells (1 × 105 cells/mouse) were used as negative control. Statistical anal-
yses were performed by the Mann-Whitney unpaired T test for nonparametric measures using the GraphPad 
Prism 4.0 Software (GraphPad Software, Inc, La Jolla, CA).
Analysis of splenocytes from B16F10 challenged mice. Spleens were removed from sacrificed 
mice according to Kalli et al.45. Frequency of memory T lymphocytes was assessed ex vivo on splenocytes 
stained by the following conjugated mAbs: CD3-BV510 (BD PharMingen, Haryana, India), CD4-APC-eFluor 
780, CD8-PE-Cy7, CD44- PE (Thermo Scientific,Waltham, MA, USA). To assess ex vivo the percentages of 
non-lymphoid APCs (monocytes and DCs), splenocytes were labelled with the following conjugated mAbs: 
CD80- FITC (Biolegend, San Diego, CA, USA), HLA-DR-PE, CD86-APC (Thermo Scientific,Waltham, MA, 
USA). The samples were analyzed by a FACS Canto II flow-cytometer (BD Bioscience, Frankin Lake, NJ, USA) 
using FACS DIVA software. In both analyses, splenocytes were stained with Live/dead fixable violet dead cell 
stain (Thermo Scientific,Waltham, MA, USA) to exclude dead cells. Statistical analyses were performed by the 
Mann-Whitney unpaired T test for nonparametric measures using the GraphPad Prism 4.0 Software (GraphPad 
Software, Inc, La Jolla, CA).
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